Biodesix, Inc. (NASDAQ:BDSX) Receives $32.50 Consensus PT from Analysts

Biodesix, Inc. (NASDAQ:BDSX) has been given an average rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $32.50.

Several equities analysts recently issued reports on the company. Wall Street Zen raised Biodesix to a “sell” rating in a report on Saturday, September 13th. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a report on Wednesday, October 8th.

Insider Buying and Selling at Biodesix

In related news, Director Jack W. Schuler purchased 174,418 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was bought at an average cost of $8.60 per share, with a total value of $1,499,994.80. Following the completion of the acquisition, the director directly owned 1,220,327 shares in the company, valued at $10,494,812.20. The trade was a 16.68% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders acquired 334,836 shares of company stock valued at $2,611,362 and sold 293 shares valued at $2,461. 30.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Biodesix

A number of institutional investors have recently made changes to their positions in BDSX. XTX Topco Ltd raised its holdings in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of Biodesix by 33.3% in the first quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock worth $78,000 after acquiring an additional 31,000 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Biodesix by 20.2% in the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company’s stock worth $304,000 after acquiring an additional 33,329 shares during the last quarter. Monashee Investment Management LLC raised its holdings in shares of Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock worth $2,532,000 after acquiring an additional 549,121 shares during the last quarter. Finally, Birchview Capital LP raised its holdings in shares of Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company’s stock worth $3,586,000 after acquiring an additional 154,937 shares during the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Stock Up 5.3%

BDSX opened at $7.79 on Wednesday. The company has a debt-to-equity ratio of 41.11, a current ratio of 2.14 and a quick ratio of 2.14. The business has a 50 day simple moving average of $8.10 and a 200-day simple moving average of $7.93. The stock has a market capitalization of $57.10 million, a P/E ratio of -1.34 and a beta of 0.98. Biodesix has a 12 month low of $3.44 and a 12 month high of $34.40.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by ($0.20). The firm had revenue of $20.02 million for the quarter, compared to analyst estimates of $18.47 million. Biodesix had a negative return on equity of 269.67% and a negative net margin of 53.66%. Biodesix has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Biodesix will post -0.35 earnings per share for the current fiscal year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.